UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
6-K
Report
of Foreign Private Issuer
Pursuant
to Rule 13a-16 or 15d-16
of
the Securities Exchange Act of 1934
For
the month of October 2025
Commission
File Number: 001-37643
PURPLE
BIOTECH LTD.
(Translation
of registrant’s name into English)
4
Oppenheimer Street, Science Park, Rehovot 7670104, Israel
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form
20-F ☒ Form 40-F ☐
Purple
Biotech
On October 20 , 2025, Purple Biotech Ltd. (the “Company”
or the “Registrant”) issued a press release “Purple Biotech Announces Receipt of Nasdaq Regarding Minimum
Bid Price Notification”, which is attached hereto as Exhibit 99.1.
| Exhibit |
|
|
| 99.1 |
|
Purple Biotech Announces Receipt of Nasdaq Minimum Bid Price Notification |
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.
| October 20, 2025 |
PURPLE BIOTECH
LTD. |
| |
|
| |
By: |
/s/
Gil Efron |
| |
|
Gil Efron |
| |
|
Chief Executive Officer |
2